<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BE5027A2-9A29-4322-AB89-41E0AF3BC9FF"><gtr:id>BE5027A2-9A29-4322-AB89-41E0AF3BC9FF</gtr:id><gtr:name>MedImmune</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9F882B87-2C77-4ACE-9F10-D0CD957B3D36"><gtr:id>9F882B87-2C77-4ACE-9F10-D0CD957B3D36</gtr:id><gtr:firstName>Giovanna</gtr:firstName><gtr:surname>Mallucci</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0E953CEB-E92F-4800-AFDB-D7FB776FE5B5"><gtr:id>0E953CEB-E92F-4800-AFDB-D7FB776FE5B5</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Collinge</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123160654"><gtr:id>6A9620A2-2ECC-4A9F-994D-FC4C50C26AF5</gtr:id><gtr:title>Normal cellular function of PrP: study of PrP null mice and conditional gene expression studies</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123160654</gtr:grantReference><gtr:abstractText>We have established that the normal form of the prion protein is an effective target for treatment in prion diseases using mouse models. We first found that we could cure mice infected with prions by removing the normal form of PrP using a genetically engineered gene switch. We found that the early holes that appear in prion diseased brains disappeared and that the mice survived without symptoms long term. We also found that early memory and motivational problems recovered along with electrical malfunction of the brain. We are using this now to develop a treatment to target PrP as a strategy.||In our group we are using new technologies to deliver this gene treatment to the brain and working to understand the mechanisms underlying the early disease and recovery.</gtr:abstractText><gtr:technicalSummary>There is widespread interest in possible therapies for CJD and related diseases. It has been assumed that PrPSc, the disease associated rogue form of one of the bodys normal proteins, prion protein, PrPc is the main neurotoxic molecule in prion disease. However, increasing evidence points to the fact that PrPSc is not directly toxic, but that as yet unidentified transient intermediate forms generated during prion replication and conversion from PrPc to PrPSc are likely to be involved in neuronal dysfunction and death. TO this end we targeted the native form of PrP, PrPc in order to remove the precursor for generation of whatever toxic species is killing cells. We first generated transgenic mice in which genetic deletion of endogenous PrPc resulted in animals being able not only to survive long term after prion infection, but they recovered early prion pathology as well as associated learning, behavioural and neurophysiological defects. We have now used a direct therapeutic approach based on our strategy of removing the native PrPc. We have used lentiviral vectors expressing short hairpin RNAs for RNAinterference directed against PrP. We have stereotactically injected these into the hippocampus of prion infected mice and have shown that this approach protects against neuronal loss, and prion replication in the targeted areas, and leads to a highly significant increased survival of 17% in treated animals after even only a single focal injection. We are now optimising the spatial and temporal requirements for PrP knockdown as an effective therapeutic strategy. We are using an empty-lentivirus for mock treatment and also comparing our results to prion infected mice without viral treatment at all.||We are currently evaluating effects of lentiviral treatment on behavioural outcomes including novel object recognition and burrowing behaviours. Early results that RNAi protects against the loss of burrowing behaviour typical of early prion disease.||We are also interested in the mechanisms of neuroprotection resulting from PrP knockout and are looking both at differential gene expression from microarray data and developing an ex-vivo system of organotypic slice culture to allow a systematic functional analysis of the effects of prion infection and PrP knockdown.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1599818</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>AD8F7FF1-B834-47E1-ABA2-614F8867C1D7</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-4</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>ISRIB-like substances</gtr:description><gtr:id>B2FA5B69-7119-47BE-B438-108A91122667</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56d08483303b30.97964556-1</gtr:outcomeId><gtr:partnerContribution>generation of compounds
in vitro testing</gtr:partnerContribution><gtr:piContribution>we will test neuroprotective effects of new compounds in mice</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>0678F440-2FA4-4D74-986E-6F25BFCCF575</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-2</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medicinal and Biological Chemistry</gtr:department><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>CC1A6518-D5D7-4A45-8C47-814F4D5EA59E</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-1</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MedImmune</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ISRIB-like substances</gtr:description><gtr:id>E16F7BDE-0D78-4328-A651-77BFE836F767</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>56d08483303b30.97964556-2</gtr:outcomeId><gtr:partnerContribution>generation of compounds
in vitro testing</gtr:partnerContribution><gtr:piContribution>we will test neuroprotective effects of new compounds in mice</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>GSK Oncology</gtr:department><gtr:description>pharmacokinetic studies on PERK inhibitors</gtr:description><gtr:id>4E46F6FD-B4FE-4192-A1AA-262A51B427F8</gtr:id><gtr:impact>Oral treatment targeting the unfolded protein response prevents prion neurodegeneration and clinical disease in mice. Moreno JA, Halliday M, Molloy C, Axten JM, Willis AE, Ortori CA, Barrett DA, Fischer PM and Mallucci GR. Science Translational Medicine, 2013, 5,206ra138. 

Sustained translational repression by eIF2a-P mediates prion neurodegeneration. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Guerra Martin M, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, M Bushell and Mallucci GR*. Nature 2012, 485, 507-11</gtr:impact><gtr:outcomeId>UXthfUnRkXZ-3</gtr:outcomeId><gtr:partnerContribution>PK and PD analyses
GSK supplied compounds
LC/MS-MS
Compound production</gtr:partnerContribution><gtr:piContribution>mechanism of neurodegeneration in prion disease and use of compounds to modulate disease progression</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>press interviews 2008</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>933F27E4-7F5A-4D72-8AFF-81B13EA8C0FD</gtr:id><gtr:impact>press interviews broadsheets science journals BBC Radio 4 science now

widespread dissemination of research</gtr:impact><gtr:outcomeId>F0E8EA61886</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>toxicology open day 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B7CDDB28-749F-4F8E-BC1E-2B25C579F9F0</gtr:id><gtr:impact>presentation to graduate students

top performer voted by students!</gtr:impact><gtr:outcomeId>N5WePEfV1G1</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature podcast</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6BFE50C6-885A-406F-9B22-F007027871C5</gtr:id><gtr:impact>nature podcast about discovery of hibernation and synaptic regeneration and role in neuroprotection</gtr:impact><gtr:outcomeId>56d08b49d3e269.66768206</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.nature.com/nature/podcast/index-2015-01-15.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival in Genova 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>55266F35-E8BF-49D4-91B9-76356A70FB88</gtr:id><gtr:impact>public interest high

public interest</gtr:impact><gtr:outcomeId>Jp2hbHTa7fr</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>nottingham inspire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BF0BA32F-95EC-4367-AC8D-F23B7BA15B3A</gtr:id><gtr:impact>400 medical students 
careers in science and medicine</gtr:impact><gtr:outcomeId>56d08bdf9fd5d0.79366680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Television interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>897E26B3-727B-4537-8E67-A807F737F5C5</gtr:id><gtr:impact>discussed our research which was hailed as &amp;quot;turning point in search for medicines to control and prevent Alzheimer's&amp;quot;</gtr:impact><gtr:outcomeId>56d08a9c698aa2.59536129</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/news/health-24462699.</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>work highlighted British Neuroscience Bulletin 2012</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B0A0AC4C-2275-4BB0-A789-FB32468EDD4C</gtr:id><gtr:impact>highlight of groups reseracj

generated much interest adn phd applications</gtr:impact><gtr:outcomeId>agXmaFLQsCx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Anne Silk Lecturer, Royal Society of Medicine, London, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>071515F9-9F55-4ACE-9587-338F68704E0D</gtr:id><gtr:impact>public lecture on progress in treatment of neurodegeneration</gtr:impact><gtr:outcomeId>56d08965326da7.46690813</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.rsm.ac.uk/events/events-listing/2013-2014/groups/public-engagement-programme/pee07-anne-silk-lecture-neurodegeneration-from-molecules-to-medicines.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>mrc annual report</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C78269B8-67E8-405C-9A80-ABC740D7DBDF</gtr:id><gtr:impact>interviewed as one of MRC's 'people behind discovery'

positive feedback, applicants to work with me</gtr:impact><gtr:outcomeId>nLGmG6TJwKC</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>media interviews 2007</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B918F26-3732-4930-BFF6-C536C17186DD</gtr:id><gtr:impact>numerous interviews to BBC radio, US radio 
science press
national press

widespread reporting in science and mass media
radio 4 interview 'science now'</gtr:impact><gtr:outcomeId>L7ppeDGPtqZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC PEN event</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41C0ED87-5BE9-4724-B60C-368AF5972F76</gtr:id><gtr:impact>public panel debate between writers and scientists &amp;quot; barriers to creativity&amp;quot; 
Royal geographical society
public debate and questions

MRC website
PEN website</gtr:impact><gtr:outcomeId>aeYQSBs6vU3</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interviews for STM paper 2013</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>491ADFC4-3D44-4E77-B378-8CBDE25CECBF</gtr:id><gtr:impact>MRC scientists halt neurodegeneration in mice (BBC 4 Today programme, 07.12) also interviews on BBC, ITV, Channel 5, Sky, CNN, ABC, Al jazeera, local radio-stations
The Independent (front page) with additional online commentary
The Daily Express (front page)
Daily Mirror (front page)
The Sun (page 4) Online version unavailable
Daily Mail (page 5)
The Guardian (page 6)
The Daily Record (page 5)
The Scotsman p13
The Herald p5 Online version unavailable
BBC online
ITV
Sky News 
Channel 4
The Daily Telegraph (page 14)
 
The story was also reported without an MRC mention in The Times (front page, online version unavailable) 
 
Plus...innumerable regional newspapers, radio and TV outlets - particularly in the Leicester area!! - and international outlets from CNN to ABC to The Times of India, Time magazine, Spanish, Italian, Brazilian, Polish, Turkish, French and German outlets. 
A pill for neurodegenerative disease? Not yet, but we're getting closer (BBC News Online)
The Guardian
SKY News
BBC World Service 
ITV
BBC World Business Report
Radio 5
BBC Breakfast
 
The Daily Mirror (page 8) highlighted the research and asked what other diseases can we hope to defeat. Online version unavailable
The Sunday Times, News Review page 2, Vivienne Parry
 (BBC News Online) The Guardian
SKY News
BBC World Service
ITV
BBC World Business Report
Radio 5
 
The Daily Mirror (page 8) highlighted the research and asked what other diseases can we hope to defeat. Online version unavailable
The Sunday Times, News Review page 2, Vivienne Parry

Huge interest into the Unit's research</gtr:impact><gtr:outcomeId>arCS6vfMSJn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Unit Open Day 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF8171FD-BC17-4C77-B215-FF1432374D8E</gtr:id><gtr:impact>Over 500 members of the public visited the Unit

Members of the public were very appreciative.
Students asked to come and carry out work experience in the Unit.</gtr:impact><gtr:outcomeId>E5hrZVUaXQn</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://tox.mrc.ac.uk/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>work experience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D3378929-3E96-4515-B138-A5EAF0773AE0</gtr:id><gtr:impact>work student for 1 week in my lab
work experience undergraduate for 10wks

positive experience further applicants</gtr:impact><gtr:outcomeId>NYM6TauQLm5</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>schools careers in science talks</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>910EA2E2-6B9D-4F5C-ABB4-F212E61E94A7</gtr:id><gtr:impact>pupils interested in science
work experience in my lab

work experience and science interests</gtr:impact><gtr:outcomeId>gBjVEV6ve4W</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>nottingham inspire</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>71EB5693-1C72-4E8B-9389-0A08615483C2</gtr:id><gtr:impact>400 medical students 
careers in science and medicine</gtr:impact><gtr:outcomeId>56d08be2d5e2f8.73697397</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>biology in action</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9284FD55-EC36-4825-BCE8-832EB926F55B</gtr:id><gtr:impact>Biology in Action is a very popular annual day, which sets out to give students a stimulating day of biology in five wide-ranging sessions, and helps them and their teachers keep up to date with developments and issues. We aim to provide students with inspiration to pursue their studies at a higher level through talks that go beyond the curriculum.</gtr:impact><gtr:outcomeId>56d08a0fa374c5.54745992</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frank May Medal for Excellence in Research and Outstanding Future Promise; University of Leicester, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BE4F1E05-BDFA-4862-A2FE-6A1FA905A850</gtr:id><gtr:impact>public lecture discussing medical advances</gtr:impact><gtr:outcomeId>56d089ca780131.48883963</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC radio interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3534BC5-A61A-44F3-BBC1-D32C507628AC</gtr:id><gtr:impact>naked scientist radio interview about hibernation and Alzheimer's</gtr:impact><gtr:outcomeId>56d08ba44edf59.95209154</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.thenakedscientists.com/HTML/podcasts/naked-scientists/show/20160119/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UK Conference of Science Journalists 2012</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>14F4D67D-B2B2-4D52-882E-BD1B2FC2F185</gtr:id><gtr:impact>dialogue with science writers

interest in science reporting</gtr:impact><gtr:outcomeId>mRbezoHn64s</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NEUROPRION Use of RNAi for treatment of inherited prion disease (14.4m euros across 41 participants)</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>7C232C7F-0CC4-41F9-9111-9F88FB90FB99</gtr:id><gtr:outcomeId>F83FD15D3080</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC Neuroscience strategy board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C562A049-264A-4DFB-87DD-47BAE34EE71A</gtr:id><gtr:outcomeId>tqjS6VZG34f</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of MRC Neuroscience and Mental Health Board</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C22A61E9-AF38-4D21-92F4-DACFB352758E</gtr:id><gtr:outcomeId>58b98ff6670522.11519917</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>leicester neuroscience steering committee</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>A5979BDE-87B1-4BA9-91EA-2096E5263997</gtr:id><gtr:outcomeId>Dj6YrMSFGd2</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>RSM clinical neuroscience council</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>54FC4130-E16A-4D0A-8C26-A13D3B701B4F</gtr:id><gtr:outcomeId>fiuVEwEjjmY</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>cre deleter mice in neurons
floxed prp mice
crossed led to adult onset knockout of prp in neurons</gtr:description><gtr:id>937EC55A-BA51-4581-8A5F-429F5731B762</gtr:id><gtr:impact>reversal prion disease widely used mouse model</gtr:impact><gtr:outcomeId>rrb1ZQFHKHB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>NFH-Cre/MloxP mice</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>79316D71-D032-43AF-9175-687AB4C633B7</gtr:id><gtr:title>Cooling-induced SUMOylation of EXOSC10 down-regulates ribosome biogenesis.</gtr:title><gtr:parentPublicationTitle>RNA (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bb43eadc376abbf6c6d96b46a2f16b0"><gtr:id>2bb43eadc376abbf6c6d96b46a2f16b0</gtr:id><gtr:otherNames>Knight JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-8382</gtr:issn><gtr:outcomeId>56d08378eb4de5.27220114</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F88D0EFC-BF35-427D-8D4B-834A4B5917EC</gtr:id><gtr:title>RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3.</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/638c314c0ef6e190e8a7f3529ecb699f"><gtr:id>638c314c0ef6e190e8a7f3529ecb699f</gtr:id><gtr:otherNames>Bastide A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>58b98ce0cfc7c0.51419460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB68F8B2-3F49-4312-B9AE-F10FEFA14CA1</gtr:id><gtr:title>Targeted knock-down of cellular prion protein expression in myelinating Schwann cells does not alter mouse prion pathogenesis.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4583d2e0c3628afec83975bf615f1319"><gtr:id>4583d2e0c3628afec83975bf615f1319</gtr:id><gtr:otherNames>Halliez S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_14120_20_23388201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AACB2439-D382-4651-B98A-857F8DB15C6E</gtr:id><gtr:title>RNAi for the treatment of prion disease: a window for intervention in neurodegeneration?</gtr:title><gtr:parentPublicationTitle>CNS &amp; neurological disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1871-5273</gtr:issn><gtr:outcomeId>nhf4ZHLKSnP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD4D7BB1-3B49-44D3-8832-DD4A30F61F17</gtr:id><gtr:title>Rescuing neurons in prion disease.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/176e57771a74564a08aa5ee42a02c1ed"><gtr:id>176e57771a74564a08aa5ee42a02c1ed</gtr:id><gtr:otherNames>Verity NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>pm_14120_20_21158739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>429B8384-584A-44CE-81AB-55C4DA4E2931</gtr:id><gtr:title>Therapy for prion diseases: Insights from the use of RNA interference.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>sbz7g4fiK7k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>403F056A-FBA4-4710-A964-810D02567EEE</gtr:id><gtr:title>Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>ckrXg8S9AD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28495C1A-66FD-4BC1-9E16-9102DCFA3C88</gtr:id><gtr:title>Can mutations of prion protein shed light on its normal function?</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>oVWwTWQNRuz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E85BA1BC-E4E5-4CB4-8479-8550933AC4FD</gtr:id><gtr:title>Sustained translational repression by eIF2a-P mediates prion neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a45accd461e1e9d4d6142f0ea8b377b"><gtr:id>4a45accd461e1e9d4d6142f0ea8b377b</gtr:id><gtr:otherNames>Moreno JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_14120_20_22622579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19B35238-530F-44FA-ACC4-678DC237B709</gtr:id><gtr:title>Review: Modulating the unfolded protein response to prevent neurodegeneration and enhance memory.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>56d08342653605.31836527</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2835CB1-D9CE-4F00-B5BA-89E42F6C20B6</gtr:id><gtr:title>Update on Creutzfeldt-Jakob disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>pm_14120_10_15542971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42CDA081-2AAC-41B1-9366-BCAB8D4317EE</gtr:id><gtr:title>Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice.</gtr:title><gtr:parentPublicationTitle>Molecular pain</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cc0219873a39ba68d81717aa20a8ab9"><gtr:id>9cc0219873a39ba68d81717aa20a8ab9</gtr:id><gtr:otherNames>Nassar MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1744-8069</gtr:issn><gtr:outcomeId>455C2EAF206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B56BF28-46A6-424B-ABB2-A3DFDE34C1E5</gtr:id><gtr:title>The role of GPI-anchored PrP C in mediating the neurotoxic effect of scrapie prions in neurons.</gtr:title><gtr:parentPublicationTitle>Current issues in molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d99597304c2ceddf5e693f3dc27c46"><gtr:id>56d99597304c2ceddf5e693f3dc27c46</gtr:id><gtr:otherNames>Radford HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1467-3037</gtr:issn><gtr:outcomeId>dVi4X9kwEjM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4705950-7B35-4499-BFB6-4C2E90CCA90B</gtr:id><gtr:title>miRNAs-19b, -29b-2* and -339-5p show an early and sustained up-regulation in ischemic models of stroke.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d8c307abe47ce905f84c424ac37145"><gtr:id>a6d8c307abe47ce905f84c424ac37145</gtr:id><gtr:otherNames>Dhiraj DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>As9Gf95u9rw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3081B6FC-5181-4104-8102-5B973632AC75</gtr:id><gtr:title>Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2003-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14120_10_14593181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5618087-A9B5-4164-BC05-4DE754D1E73F</gtr:id><gtr:title>Targeting the unfolded protein response in neurodegeneration: A new approach to therapy.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>pm_14120_20_24035917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE8F89EF-426C-4020-97E2-7F7958227657</gtr:id><gtr:title>Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>1999-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14120_10_10506086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A896CA5-EDF6-48B3-B37B-DAF78DC4DE18</gtr:id><gtr:title>The unfolded protein response: mechanisms and therapy of neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f53b11de0d73641d654e1123e43facda"><gtr:id>f53b11de0d73641d654e1123e43facda</gtr:id><gtr:otherNames>Smith HL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>58b98d2252bef8.53009065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52CD4ABE-699B-4AEA-97D4-D63353CC129C</gtr:id><gtr:title>Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a45accd461e1e9d4d6142f0ea8b377b"><gtr:id>4a45accd461e1e9d4d6142f0ea8b377b</gtr:id><gtr:otherNames>Moreno JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_14120_20_24107777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3356298E-5345-4796-A006-0A96AA03B654</gtr:id><gtr:title>Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d0834235b706.13023737</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB24FD59-EAA9-47F8-9F39-0BABDAE4E000</gtr:id><gtr:title>Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2002-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>pm_14120_10_11823413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B55EC86D-DEB7-454C-9B6D-3FE31CA93D49</gtr:id><gtr:title>Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c24855ecb6f14958c378c4a4b3352d2f"><gtr:id>c24855ecb6f14958c378c4a4b3352d2f</gtr:id><gtr:otherNames>Tufi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-7392</gtr:issn><gtr:outcomeId>KSyW2xJm23F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D500C3C0-2B96-4518-BFC6-C449162E71E2</gtr:id><gtr:title>Dysfunction and recovery of synapses in prion disease: implications for neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a45accd461e1e9d4d6142f0ea8b377b"><gtr:id>4a45accd461e1e9d4d6142f0ea8b377b</gtr:id><gtr:otherNames>Moreno JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>ENBCEt21cXQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7726254-9C46-477F-8285-92A4546C9D59</gtr:id><gtr:title>Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>C5E8C3C067B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F53FF332-CEAC-4B30-8591-4AB4A26370D9</gtr:id><gtr:title>Rational targeting for prion therapeutics.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1471-003X</gtr:issn><gtr:outcomeId>pm_14120_10_15611724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2970F93C-DE12-4273-9641-398C483E58D3</gtr:id><gtr:title>Spreading proteins in neurodegeneration: where do they take us?</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90cffc3bbd002d1184acf786baea9f47"><gtr:id>90cffc3bbd002d1184acf786baea9f47</gtr:id><gtr:otherNames>Mallucci G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14120_20_23518708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EAE7A7C-EA8D-4CC7-88EA-C459151ACF3A</gtr:id><gtr:title>Prion neurodegeneration: starts and stops at the synapse.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>GJAvxVTStHN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEBCC664-B83A-4843-A35A-E53962DED33B</gtr:id><gtr:title>PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b63bf0ee58edc8bb7309751c416fdc30"><gtr:id>b63bf0ee58edc8bb7309751c416fdc30</gtr:id><gtr:otherNames>Radford H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>56d08341e62724.55689293</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123160654</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>